20260615 Codex 產生 EBM 報告，例二
Documented Adverse Effects of Semaglutide and Recent Evidence on Management
Clinical Question
What are the documented adverse effects of semaglutide, and what recent evidence is available regarding their management?
PECO framework: adults or adolescents receiving semaglutide; exposure to injectable or oral semaglutide, especially during initiation and dose escalation; comparator placebo, other glucose-lowering/anti-obesity therapy, or non-exposure; outcomes include gastrointestinal symptoms, serious gastrointestinal/biliary events, pancreatitis, kidney injury, hypoglycemia, retinopathy, aspiration, hypersensitivity, thyroid C-cell tumor warning, psychiatric and ophthalmic safety signals, discontinuation, and practical management.
Bottom Line
Semaglutide adverse effects are dominated by dose-related gastrointestinal symptoms, especially nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, reflux, and eructation. Most are managed by slower titration, temporary dose hold or dose reduction, hydration, smaller low-fat meals, constipation/diarrhea treatment, and careful follow-up. Serious events are uncommon but clinically important: pancreatitis symptoms require immediate discontinuation and evaluation; gallbladder symptoms require biliary workup; vomiting/diarrhea with dehydration requires renal-function assessment; visual symptoms require urgent eye evaluation; and perioperative teams should be informed because delayed gastric emptying may increase aspiration risk.
Recent evidence strengthens three points: GLP-1 receptor agonists increase cholelithiasis and GERD risk in randomized trials; management of GI adverse effects should emphasize individualized titration rather than automatic discontinuation; and the perioperative approach has shifted toward risk stratification rather than universal prolonged withholding.
Search Strategy
Sources searched: PubMed/MEDLINE, DailyMed/FDA structured product labeling, FDA and EMA safety communications where identifiable, and recent society guidance.
Key query:
(semaglutide OR GLP-1 receptor agonist)
AND (adverse effects OR safety OR gastrointestinal OR pancreatitis OR gallbladder OR gastroparesis OR NAION OR aspiration)
AND (management OR recommendations OR guidance OR systematic review OR cohort)Selection emphasis: current official labeling, systematic reviews/meta-analyses, safety guidance, large observational studies for rare harms, and clinically actionable management papers.
Documented Adverse Effects and Management
| Adverse effect / safety issue | Documented evidence | Clinical management |
|---|---|---|
| Common gastrointestinal symptoms nauseadiarrheavomitingconstipationabdominal paindyspepsia/GERD |
Latest Wegovy label lists nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%, abdominal pain 20%, headache 14%, fatigue 11%, dyspepsia 9%, dizziness 8%, abdominal distension 7%, eructation 7%, flatulence 6%, gastroenteritis 6%, and GERD 5% with weekly 2.4 mg injection in adult weight-loss trials. GI symptoms were the most common reason for discontinuation. | Start low and titrate gradually. If symptoms are moderate or persistent, pause escalation, extend the current dose step, reduce to the prior tolerated dose, or temporarily hold. Counsel smaller meals, slower eating, avoiding high-fat meals, hydration, and stopping when full. Treat constipation, diarrhea, reflux, and nausea symptomatically when appropriate. Reassess for red flags rather than attributing all abdominal symptoms to medication. |
| Severe GI reactions / gastroparesis-like symptoms | Official labeling states severe GI adverse reactions occur more often with Wegovy than placebo and Wegovy is not recommended in severe gastroparesis. Delayed gastric emptying is pharmacologic and can be clinically relevant. | Avoid or use specialist judgment in known severe gastroparesis. For persistent vomiting, inability to maintain intake, severe constipation, suspected ileus/obstruction, or weight-loss-associated malnutrition, hold semaglutide and evaluate. Consider gastroenterology referral if symptoms persist after stopping. |
| GERD and cholelithiasis | A 2025 systematic review/meta-analysis of 55 RCTs and 106,395 participants found increased cholelithiasis risk (RR 1.46; 95% CI 1.09-1.97; about 2 more cases per 1000) and probable increased GERD risk (RR 2.19; 95% CI 1.48-3.25; about 4 more cases per 1000). Wegovy label reports cholelithiasis 1.6% vs 0.7% placebo and cholecystitis 0.6% vs 0.2% placebo in adult injection weight-loss trials. | For RUQ pain, fever, jaundice, persistent nausea/vomiting, or abnormal liver tests, evaluate for gallstones/cholecystitis with labs and ultrasound as appropriate. Manage GERD with lifestyle, acid suppression when indicated, dose adjustment if temporally related, and differential diagnosis for alarm symptoms. |
| Acute pancreatitis | Labeling warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Wegovy. Recent RCT meta-analysis did not show a clear increase in most serious GI/biliary events beyond cholelithiasis and GERD, but pancreatitis remains a labeled serious risk. | Educate patients to report persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting. If suspected, discontinue semaglutide immediately and initiate standard pancreatitis evaluation and management. Do not rechallenge unless a specialist determines an alternative cause and risk-benefit strongly favors it. |
| Acute kidney injury from volume depletion | Postmarketing reports include acute kidney injury, sometimes requiring hemodialysis, usually in the setting of nausea, vomiting, diarrhea, and dehydration. | Check renal function and electrolytes in patients with substantial vomiting/diarrhea, frailty, CKD, diuretic/RAAS inhibitor use, or poor oral intake. Hold semaglutide during significant dehydration or acute illness. Rehydrate and restart cautiously only after clinical recovery. |
| Hypoglycemia | Semaglutide alone has low intrinsic hypoglycemia risk, but risk rises with insulin or insulin secretagogues. Wegovy label recommends glucose monitoring and considering insulin or sulfonylurea dose reduction when starting. | Review diabetes regimen before initiation. Reduce insulin/sulfonylurea when clinically appropriate, increase self-monitoring/CGM review during titration, and educate on hypoglycemia treatment. This is especially important with reduced caloric intake. |
| Diabetic retinopathy complications | Semaglutide labeling cites higher diabetic retinopathy complications in a 2-year trial of semaglutide 0.5/1 mg in adults with type 2 diabetes and high cardiovascular risk, especially among those with baseline retinopathy. Rapid glycemic improvement can transiently worsen retinopathy. | Assess baseline eye disease in diabetes. Arrange appropriate retinal follow-up for known diabetic retinopathy, rapid HbA1c reduction, or visual symptoms. Do not ignore new floaters, vision loss, or visual field changes. |
| NAION / sudden visual loss signal | Recent observational ophthalmology studies and EMA PRAC review raised concern for non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare semaglutide-associated adverse effect. Causality and absolute risk remain uncertain, but the signal is clinically important because vision loss may be irreversible. | Advise urgent ophthalmic/emergency evaluation for sudden painless vision loss, visual field defect, or acute vision deterioration. Discuss uncertainty with patients who have prior NAION or major optic nerve risk factors; coordinate with ophthalmology when risk is high. |
| Pulmonary aspiration during anesthesia or deep sedation | Labeling notes rare postmarketing aspiration reports despite usual fasting. Multisociety 2024 perioperative guidance recommends individualized risk assessment because delayed gastric emptying varies and evidence is limited. | Patients should tell anesthesia/endoscopy/surgical teams they use semaglutide. Higher risk: escalation phase, high dose, active GI symptoms, known gastroparesis, or other delayed-emptying risks. Management may include deferring elective procedures during active symptoms, liquid diet pre-procedure, point-of-care gastric ultrasound where available, anesthesia precautions, or selective medication hold based on team judgment. |
| Hypersensitivity | Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported. Prior serious hypersensitivity to semaglutide or excipients is a contraindication. | Discontinue and treat promptly per anaphylaxis/angioedema standards. Do not rechallenge after serious hypersensitivity without specialist input. |
| Thyroid C-cell tumor warning | Boxed warning is based on rodent C-cell tumors; human relevance is unknown. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. | Screen history before prescribing. Counsel about neck mass, dysphagia, dyspnea, or persistent hoarseness. Routine calcitonin or thyroid ultrasound monitoring has uncertain value and may cause unnecessary procedures. |
| Psychiatric safety / suicidal ideation | A 2024 real-world cohort study in Nature Medicine did not show higher suicidal ideation risk with semaglutide compared with non-GLP-1 anti-obesity or anti-diabetes medications. FDA previously reviewed reports and did not find evidence of a clear causal relationship. This remains an area for pharmacovigilance rather than a proven causal adverse effect. | Continue usual psychiatric screening and monitor mood, especially in patients with depression, eating disorders, prior suicidality, or major body-image distress. Do not abruptly stop effective therapy solely because of unproven signal, but escalate urgently if suicidal ideation emerges. |
| Hair loss, dysesthesia, fatigue, dizziness | Wegovy labeling includes hair loss and dysesthesia among reactions more frequent than placebo in weight-loss trials, with dysesthesia especially prominent in higher-dose 7.2 mg injection trials. Hair loss may also relate to rapid weight loss or nutritional deficiency. | Assess dose timing, nutrition, protein intake, iron/ferritin, thyroid status, and weight-loss velocity when clinically indicated. Manage symptomatically; consider slower weight loss, dose adjustment, or dermatology/neurology referral for severe or atypical symptoms. |
| Compounded or unapproved semaglutide products | FDA has warned that compounded GLP-1 products are not FDA-approved and may involve dosing errors or salt forms such as semaglutide sodium/acetate that are not the same as approved semaglutide products. | Prefer FDA-approved products when available. If a patient used a compounded product, verify concentration, dosing units, source, and adverse-event chronology. Report serious suspected adverse events to FDA MedWatch. |
Red Flags Requiring Same-Day Evaluation or Drug Hold
- Persistent severe abdominal pain, especially radiating to the back, with or without vomiting: hold semaglutide and evaluate for pancreatitis.
- RUQ pain, fever, jaundice, or persistent postprandial pain: evaluate for gallbladder disease.
- Repeated vomiting, inability to maintain hydration, syncope, oliguria, or CKD: hold and check renal function/electrolytes.
- Sudden vision loss or acute visual field defect: urgent ophthalmology/emergency evaluation.
- Anaphylaxis, angioedema, airway symptoms, or generalized urticaria: emergency care and discontinue.
- Upcoming anesthesia, endoscopy, or deep sedation with active GI symptoms: alert procedural team before the procedure.
Evidence Table
| Source | Design / population | Main finding | Appraisal |
|---|---|---|---|
| DailyMed Wegovy label, published 2026-05-22 | Current US structured product label | Defines contraindications, boxed warning, common adverse reactions, serious warnings, and monitoring/management instructions. | Authoritative labeling Best source for documented labeled adverse effects, but label frequencies depend on trial populations and reporting rules. |
| Chiang et al., Gastroenterology 2025 | Systematic review/meta-analysis; 55 placebo-controlled RCTs; 106,395 participants | Increased cholelithiasis and probable increased GERD; little or no effect on other serious GI/biliary outcomes in pooled RCTs. | Higher certainty for common GI/biliary outcomes Rare harms may remain underpowered. |
| Jalleh et al., Lancet Gastroenterol Hepatol 2024 | Personal View / mechanistic review | Summarizes gastric-emptying physiology and highlights uncertainty in pre-procedure management. | Mechanistic guidance Useful for clinical reasoning; not a formal trial. |
| Kindel et al., multisociety perioperative guidance 2024 | Practice guidance from AGA, ASMBS, ASA, ISPCOP, SAGES | Supports risk-stratified perioperative management of GLP-1 receptor agonists rather than a one-size-fits-all approach. | Consensus guidance Evidence base still limited; local anesthesia policy matters. |
| Wharton et al., Postgrad Med 2022 | Clinical recommendations for GI adverse-effect management | Practical strategies include dietary counseling, slower escalation, dose reduction/temporary interruption, and symptom-directed therapy. | Practical expert guidance Management recommendations are not all RCT-tested. |
| Cai et al., JAMA Ophthalmology 2025 | Multicenter observational study | Evaluated semaglutide and NAION signal in real-world data. | Signal evaluation Rare outcome; confounding and detection bias remain possible. |
| Wang et al., Nature Medicine 2024 | Real-world cohort study | Semaglutide was not associated with increased suicidal ideation compared with non-GLP-1 comparator medications. | Reassuring observational evidence Still monitor high-risk patients clinically. |
Practical Prescribing and Follow-Up Checklist
- Before initiation: check indication, pregnancy plans, MTC/MEN2 history, pancreatitis/gallbladder history, diabetic retinopathy status, renal function risk, current insulin/sulfonylurea use, psychiatric risk, and planned procedures.
- During escalation: ask specifically about nausea, vomiting, constipation, diarrhea, reflux, abdominal pain, hydration, urinary output, hypoglycemia, palpitations, and vision changes.
- For GI intolerance: pause escalation first; consider dose reduction or temporary hold before permanent discontinuation if no red flags.
- For serious suspected adverse effects: hold semaglutide, evaluate the syndrome directly, and report serious suspected events to pharmacovigilance systems.
- For procedures: communicate semaglutide dose, timing, escalation status, and active GI symptoms to anesthesia/endoscopy/surgery teams.
Applicability and Limitations
Adverse-effect frequencies differ by formulation, dose, indication, comparator, trial duration, diabetes status, concomitant drugs, and weight-loss velocity. Rare harms such as NAION, aspiration, severe pancreatitis, and severe kidney injury are better captured by observational and postmarketing data, but those data are more vulnerable to confounding and reporting bias. This report summarizes evidence for clinicians and does not replace product labeling, local policies, or patient-specific judgment.
References
- DailyMed. WEGOVY (semaglutide) injection/tablet prescribing information. Published 2026-05-22. DailyMed label.
- Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025;169(6):1268-1281. doi: 10.1053/j.gastro.2025.06.003. PubMed: 40499738.
- Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957-964. doi: 10.1016/S2468-1253(24)00188-2. PubMed: 39096914.
- Kindel TL, Wang AY, Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol. 2025;23(12):2083-2085. doi: 10.1016/j.cgh.2024.10.003. PubMed: 39480373.
- Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. doi: 10.1080/00325481.2021.2002616. PubMed: 34775881.
- Cai CX, Hribar M, Baxter S, et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025;143(4):304-314. doi: 10.1001/jamaophthalmol.2024.6555. PubMed: 39976940.
- Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. doi: 10.1038/s41591-023-02672-2. PubMed: 38182782.
- Thomsen RW, Mailhac A, Lohde JB, Pottegard A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27 Suppl 2:66-88. doi: 10.1111/dom.16364. PubMed: 40196933.
- FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA safety page.
- FDA. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. FDA update.
- EMA. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines. EMA PRAC communication.
